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Abstract
Background: The response of normal tissues in cancer patients undergoing radiotherapy varies, possibly due to
genetic differences underlying variation in radiosensitivity.
Methods: Cancer patients (n = 360) were selected retrospectively from the RadGenomics project. Adverse effects
within 3 months of radiotherapy completion were graded using the National Cancer Institute Common Toxicity
Criteria; high grade group were grade 3 or more (n = 180), low grade group were grade 1 or less (n = 180).
Pooled genomic DNA (gDNA) (n = 90 from each group) was screened using 23,244 microsatellites. Markers with
different inter-group frequencies (Fisher exact test P < 0.05) were analyzed using the remaining pooled gDNA.
Silencing RNA treatment was performed in cultured normal human skin fibroblasts.
Results: Forty-seven markers had positive association values; including one in the SEMA3A promoter region (P =
1.24 × 10
-5). SEMA3A knockdown enhanced radiation resistance.
Conclusions: This study identified 47 putative radiosensitivity markers, and suggested a role for SEMA3A in
radiosensitivity.
Background
A principle determinant of the efficiency of tumor eradi-
cation following radiotherapy is the total radiation dose
given to a patient. The radiation tolerance of important
organs located at the margins of the radiotherapy target
volume is a critical issue in determining dose thresholds.
However, variation in the genetic background of indivi-
duals also contributes to the severity of radiation-related
adverse events [1-7].
Andreassen et al. have summarized the results of many
genetic association studies that used single nucleotide
polymorphisms (SNPs) as genetic markers, and compared
allele frequencies in radiosensitive and nonradiosensitive
individuals [7]. Most studies use a candidate gene
approach; with genes selected based on ontology. In par-
ticular, these studies have focused on genes involved in
processes including response to DNA damage, cell death,
cell cycle control, oxidative stress, radiation-induced
fibrogenesis, and endothelial cell damage.
Systematic microarray gene expression analyses [8-13]
and in vitro functional screening using siRNA knock-
down of gene expression [14], have been used to identify
potential radiation susceptibility genes. Significant asso-
ciation has been found between the risk of early adverse
skin reactions (EASRs) following radiotherapy, and SNP
haplotypes associated with six of 137 candidate genes
(CD44, MAD2L2, PTTG1, RAD9A, LIG3 and REV3L)
[15]. This has led to the development of a novel DNA
chip-based technique to analyze haplotype markers in
individual cancer patients [16-19].
Although positive associations between genetic mar-
kers and radiosensitivity have been found, the search for
strongly associated genetic markers has been unreward-
ing [7], and this is partly due to inadequate understand-
ing of the molecular pathology of adverse reactions
induced by radiotherapy.
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abundant and interspersed throughout the human gen-
ome, similar to SNPs. Importantly though, microsatellite
polymorphism generally exceeds that of single SNPs,
even reaching the degree of polymorphism provided by
SNP haplotypes [20]. Thus, association analyses using a
relatively small number of microsatellites should still
have adequate statistical power relative to that provided
by SNPs [20]. This is illustrated by the identification of
genes associated with rheumatoid arthritis [21], narco-
lepsy [22] and Behcet’s disease [23] using genome-wide
association studies based on microsatellites.
Hence, a genome-wide association study was per-
formed to identify candidate genes that are strongly
associated with radiosensitivity in humans. The screen
analyzed data from 23,244 microsatellites in 360 cancer
patients who had undergone radiotherapy and been
graded for normal tissue adverse reactions. Forty-seven
markers were identified as being of interest, with a role
for the involvement of SEMA3A in radiosensitivity
suggested.
Methods
Grading of patients with low and high grade
radiosensitivity
Since 2001, the RadGenomics project has enrolled more
than 3000 patients who have undergone radiotherapy.
All patients provided written informed consent to parti-
cipate in this study, which was approved by the Institu-
tional Review Board at the National Institute of
Radiological Sciences and by each collaborating institu-
tion. The acute adverse reactions of individual patients
up to three months after completion of radiotherapy
were graded according to the National Cancer Institute’s
Common Toxicity Criteria (NCICTC) version 2. We ret-
rospectively selected 180 patients, who presented with a
severe acute reaction of equal to or greater than grade
3, as a high-grade group (HGG). We also retrospectively
selected 180 patients with less than or equal to grade 1
acute reaction on any end point, as a low-grade group
(LGG). The assignment of patients to the LGG and
HGG took into consideration their cancer type, age,
gender, treatment type, and radiation dose (table 1).
Preparation of pooled DNA samples
Extraction of gDNA from whole blood was performed
using an automatic nucleic acid isolator, NA3000S (Kur-
abo, Osaka, Japan) or with the QIAamp DNA blood kit
(Qiagen, Hilden, Germany). The gDNA concentrations
were measured in triplicate using a PicoGreen double-
stranded DNA quantification kit (Invitrogen, Carlsbad,
USA) and an SF600 microtiter plate reader (Corona
Electric, Ibaraki, Japan). To reduce the amount of geno-
typing required, gDNA samples were pooled according
to the method of Collins et al [24]. Concentrations of
individual gDNA samples were adjusted to 8 ng/μL. An
equal volume of each of 90 gDNA samples from the
HGG was combined to generate the first set of pooled
gDNA and termed HGG-1. Similarly, 90 gDNA samples
from the LGG were pooled and termed LGG-1. A sec-
ond set of pooled gDNA samples was also prepared
from 90 samples of the HGG and 90 samples of the
LGG, and these were termed HGG-2 and LGG-2,
respectively.
Analysis of microsatellite markers
All microsatellite markers and the methods for microsa-
tellite analysis used in this study are described in
Tamiya et al [21]. The genomic location of the microsa-
tellite markers was investigated using the UCSC Gen-
ome Browser http://genome.ucsc.edu/cgi-bin/
hgGateway. PCR primers to amplify microsatellites were
designed to anneal at 57°C, with forward primers having
a5 ’ fluorescent label (6-FAM or HEX). PCR was per-
formed using the GeneAmp PCR system 9700 (GE
Healthcare, Amersham Place, UK) in 20 μL containing
48 ng pooled DNA, 0.5 U AmpliTaq DNA polymerase,
reaction buffer containing 1.5 mM MgCl2 (GE Health-
care, Amersham Place, UK), 5 μM of each primer, and
0.25 mM of each dNTP in 96- or 384-well plates. PCR
profile was as follows; 96°C for 5 min, 57°C for 1 min,
72°C for 1 min; 40 cycles of 96°C for 45 s, 57°C for 45 s,
72°C for 1 min. For microsatellite typing of individual
samples, PCR was performed in 12 μL containing 2 ng
D N A ,0 . 2 5UA m p l i T a qG o l dD N Ap o l y m e r a s e( G E
Healthcare, Amersham Place, UK), reaction buffer con-
taining 1.5 mM MgCl2,5μM of each primer, and 0.2
mM of each dNTP in 96- or 384-well plates and ampli-
fied as above. PCR products were denatured in Hi-Di
formamide (GE Healthcare, Amersham Place, UK) at
95°C for 3 min and separated by capillary electrophor-
esis using an ABI Prism 3700 Genetic Analyzer and
ROX size standards (GE Healthcare, Amersham Place,
UK). Analysis of fragment size and electrophoretograms
was performed using GeneScan and Genotyper software
(GE Healthcare, Little Chalfont, UK).
Statistical analysis
Allele frequencies in pooled DNA were estimated from
the height of peaks in the electrophoretogram [21].
Association of microsatellites with radiosensitivity was
assessed using Fisher exact test and 2 × 2 contingency
tables for each allele. The lowest P value for any allele
of a particular microsatellite was used in analysis for
that microsatellite marker and significance was set at
0.05. To account for multiple testing across the microsa-
tellite markers, the P values of the second screening
were adjusted using the false discovery rate (FDR)
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Characteristic initial genome screen focused screen Difference between groups (P)
LGG-1 HGG-1 LGG-2 HGG-2
(n = 90) (n = 90) (n = 90) (n = 90)
Age at RT
Mean ± SD 59.7 ± 14.6 59.7 ± 11.5 62.5 ± 12.8 59.5 ± 11.1 0.434
Range 26-89 38-83 38-88 21-79
Family history of cancer 33 (36.7%) 23 (25.6%) 42 (46.7%) 37 (41.1%) 0.129
Cancer type
Breast 42 7 42 7
Cervical 15 27 15 27
Esophageal 4 15 4 15
Head and neck 10 30 9 31
Lung 18 10 19 9
Prostate 1 1 1 1
TNM classification
T1 50 13 46 22
T2 30 30 27 35
T 3 8 3 41 12 6
T4 2 13 6 7
N0 72 43 72 40
N1 12 30 13 27
N2 6 10 4 17
N 3 0615
N 4 0001
M0 90 78 87 81
M1 0 12 3 9
Dose of radiotherapy (Gy)*
Breast 49.6 ± 1.4 49.9 ± 0.6 0.602
Cervical 50.2 ± 4.3 50.7 ± 3.9 0.704
Esophageal 54.2 ± 11.3 50.7 ± 8.6 0.776
Head and neck 65.0 ± 5.9 65.3 ± 3.9 0.8
Lung 52.1 ± 8.9 51.4 ± 10.8 0.715
Grade of adverse event**
0 30 0 25 0
1 60 0 65 0
20 0 0 0
3 0 84 0 74
40 6 0 1 6
* Average dose was obtained only for patients treated with photon therapy. Prostate cancer was treated using brachytherapy or particle therapy.
**Adverse event mainly: dermatitis for breast cancer; diarrhea, bone marrow suppression for cervical cancer; dysphagia, bone marrow suppression for esophageal
cancer; dermatitis, mucositis for head and neck cancer; pneumonitis, bone marrow suppression for lung cancer; dysuria for prostate cancer.
Abbreviations: LGG = Low grade group, HGG = High grade group, RT = radiotherapy, TNM = Tumor Node Metastasis.
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Association between particular alleles of a microsatellite
and grade of radiosensitivity was performed using the
Cochran-Armitage test for trend [26].
Cell culture conditions
Normal human skin fibroblast NB1RGB cells were
obtained from Riken Cell Bank (Tsukuba, Japan) and
maintained in Eagle’s minimum essential medium (Nis-
sui, Tokyo, Japan) supplemented with 10% fetal bovine
serum (FBS) and nonessential amino acids under a
humidified atmosphere of 5% CO2 at 37°C.
siRNA treatment of human fibroblast cultures
T w od i f f e r e n ts i R N A s( 1 :1 35598, 2: 135597, Applied
Biosystems/Ambion, Austin, USA) designed for the
human SEMA3A gene were used to treat cells by reverse
transfection. Cultured cells were harvested by incubation
with 0.05% trypsin, 0.53 mM EDTA in phosphate-buf-
fered saline (trypsin-EDTA/PBS) for 5 min at room tem-
perature, followed by inactivation of the trypsin by
adding complete culture medium. The number of cells
with a diameter of 12 μm was measured using the Z1
Coulter Particle Counter (Beckman Coulter, Brea, USA).
Transfection complexes were prepared in 266.6 μl Opti-
MEM serum free medium by mixing 5.4 μLo fs i P O R T
NeoFX Transfection Reagent (Applied Biosystems/
Ambion, Austin, USA) for 10 min prior to adding 2.7 μl
of 10 μM siRNA (Applied Biosystems/Ambion, Austin,
USA) for 10 min. The cell suspension containing 27,000
cells in 725.3 μl was added to the transfection com-
plexes and the mixture plated onto a 35 mm plastic
dish. Cells were maintained under a humidified atmo-
sphere of 5% CO2 at 37°C for 24 hours. The mock con-
trol cells were treated similarly, except the transfection
complexes were prepared without siRNA. The transfec-
tion medium was then changed to complete culture
medium, and cells were maintained for the indicated
time.
Western blotting
The post-transfection complete culture medium was
recovered at the indicated time, centrifuged at 12,000 ×
g for 5 min and the supernatant transferred to a micro-
fuge tube and stored at -30°C until use. Fifteen μL ali-
quots of supernatant were mixed with 5 μLo fl o a d i n g
dye, incubated at 80°C for 10 min and loaded onto
NuPAGE 4-12% polyacrylamide Bis-Tris gradient gels
(Invitrogen, Carlsbad, USA) under denaturing condi-
tions. Proteins in the gels were then transferred onto
PVDF membranes by the iBlot Gel Transfer Device
(Invitrogen, Carlsbad, USA). The membranes were
probed with primary rabbit polyclonal antibody SEMA
(H-300) against amino acids 103-402 of the human
protein from SEMA3A (Santa Cruz Biotechnology, Santa
Cruz, USA). A secondary donkey anti-rabbit IgG conju-
gated to horseradish peroxidase (GE Healthcare, Amer-
sham Place, UK) was used to detect protein bands using
an ECL Advance Western Blotting Detection Kit (GE
Healthcare, Little Chalfont, UK).
Radiosensitivity assay of siRNA-treated human skin
fibroblast cultures
Cells cultured for 48 hours following replacement of the
siRNA transfection medium, were harvested by incuba-
tion with trypsin-EDTA/PBS for 5 min at room tempera-
ture. Trypsin was then inactivated by adding complete
culture medium, and the number of cells with a diameter
of more than 12 μm was counted using a Z1 Coulter Par-
ticle Counter. The appropriate number of cells (1,000
cells for 0 Gy, 1,500 cells for 1 Gy, 3,000 cells for 2 Gy,
6,000 cells for 3 Gy and 12,000 cells for 4 Gy) were then
irradiated at room temperature with 200 kV X-rays
(20 mA) with 0.5 mm aluminum and 0.5 mm copper fil-
ters. Immediately after irradiation, cells were plated onto
100 mm (0 and 1 Gy) or 150 mm (2-4 Gy) plastic dishes,
and cultured under a humidified atmosphere of 5% CO2
at 37°C for 2 weeks. Cells were washed with PBS, then
fixed in 100% methanol for a few minutes at room tem-
perature. After removing the methanol, the cells were
dried for 30 minutes and then stained with 3% Giemsa
solution for 2 hours. Colonies consisting of more than 50
cells were scored as survivors. Experiments were per-
formed with triplicate plating of cells. Relative colony
survival as a function of irradiated dose was tested using
the linear-quadratic model [27].
Results
Genome-wide association study
The entire human genome was screened using 23,244
microsatellite markers and one set of the pooled DNA
from each group (HGG-1 and LGG-1). This analysis
identified 3,052 markers with allele/s that showed signif-
icantly different estimated frequency (P < 0.05) between
the two groups (see figure 1A). These markers were
further analyzed in the second round screening with the
remaining set of pooled DNA samples from each group
(HGG-2 and LGG-2). A total of 101 markers had allele/
s with significantly different estimated frequency (P <
0.05) between the two groups, and had similar peak
association patterns in the data from the first and sec-
ond DNA pools (see figure 1B). The FDR of the markers
analyzed in the second round screening was then esti-
mated to correct for the effect of multiple comparisons.
After correction for the multiple comparisons per-
formed, 47 autosomal markers had a FDR < 0.05, and so
were significantly associated with radiosensitivity in this
study. These markers are summarized in table 2.
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The genomic location of the 47 positive markers was
determined using the UCSC Genome Browser. Four
markers were within 15 kb upstream of the transcription
s t a r ts i t ef o rt h en e a r e s tg e n e( t a b l e3 ) .T oc o n f i r mt h e
associations observed in the pooled DNA analysis, these
four markers were individually typed in all 360 patients.
The particular alleles of D1S0288i and D7S0338i found
to be statistically significantly associated with radiosensi-
tivity in the experiments using pooled DNA, were also
found to be so when experiments using individual DNA
samples were used (table 3). One of the positive mar-
kers, D7S0338i, was selected for further study as it had
the strongest association with radiosensitivity.
Detailed association analysis of the D7S0338i marker
Allelic distribution of the marker D7S0338i is repre-
sented in additional file 1. Eleven alleles were identified
in D7S0338i, with three major alleles (292 bp, 294 bp and
296 bp) accounting for more than 90% of the alleles in
the study population (see table 4 and additional file 1).
Among them, two alleles (292 bp and 296 bp) had an
overall P value < 0.05. Association analysis revealed the
292/292 genotype was associated with risk reduction
(odds ratio: 0.490, 95% CI: 0.271-0.885), the 294/294 gen-
otype was associated with intermediate risk (odds ratio:
0.794, 95% CI: 0.321-1.966), and the 296/296 genotype
was associated with an increased risk (odds ratio: 2.861,
95% CI: 1.417-5.774) (see table 5). Interestingly, the het-
erozygote individuals carrying the risk reducing and risk
increasing alleles (292/296) had intermediate risk (odds
ratio: 1.152, 95% CI: 0.727-1.824). This suggests the
inter-allele relationship may not behave in the usual
dominant-recessive manner. A linear trend was identified
between six combinations of alleles for the marker and
radiosensitivity (P = 7.228 × 10
-4) (see table 5).
Figure 1 Results of two rounds of screening of microsatellite markers for association with radiosensitivity. (A) Results of the screen of
the entire genome using 23,244 microsatellite markers and the HGG-1 and LGG-1 pooled DNAs. (B) Results of screening 3,052 markers of
interest identified in the preceding genome scan and using the HGG-2 and LGG-2 pooled DNAs. P values calculated using Fisher’s exact test and
2 × 2 contingency tables are shown. The level of significance (P < 0.05) is shown as a horizontal broken line.
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Number Marker Chr Position in hg18* Sequence of PCR primers P value FDR
5’-end 3’-end Forward Reverse 1st 2nd
1 D5S0329i 5 33286356 33286817 GAAAGAATTACACTTTGCCAA AATTGAGATGTCTAAAGGCATC 2.549E-05 5.916E-18 3.897E-15
2 D6S0876i 6 82039209 82039634 ACCACAATAAGATATCACCTCAC CATTACATTCATGCATACACATAC 0.0263 6.518E-14 1.717E-11
3 D3S0313i 3 104474152 104474509 AACCATCAGATCTTGTTAGAATTA GTAGTGGTACAGGCCTGTAGT 2.409E-07 2.082E-11 3.048E-09
4 D1S0494i 1 199551754 199551974 GTGTAAGAGCCAGCTGGAC TCTTGTTTGTGTCTGGTATTAGG 0.0066 8.736E-11 1.151E-08
5 D3S0923i 3 105397288 105397735 GGTATCATTTATCTGGATCCAC AATTCTTTCAGATGAAAGGAAG 4.025E-04 1.714E-10 2.052E-08
6 D5S0365i 5 111127178 111127405 ACACAAATAAGCATGCGC CCAGATTATCCTACCACGC 1.127E-08 1.127E-08 9.279E-07
7 D14S0444i 14 26355444 26355548 TCATAGCACTTATCACTACCTTAGG GATGAAGCCAAGGAGGAG 3.863E-08 8.37E-08 5.80E-06
8 D7S0192i 7 24587185 24587633 ATTACCATTATGGTAGGCTGAATA GCCAGACATTTGAAATCAGTAT 0.0025 3.53E-07 1.95E-05
9 D5S0292i 5 117035880 117036332 ACTTATAGGTCAGCAACCATTC GCAATTAGATGGCATTAAATTA 2.82E-04 2.27E-06 8.80E-05
10 D17S945 17 9763962 9764159 AACCAATCTGGACTCCCC CCTGAAGCCTGACCCC 4.52E-04 2.70E-06 1.02E-04
11 D4S0813i 4 122056656 122057077 TCTTCAGCATTCAGAATATGAT CAAATTGTCTTTGTTATGTACCTC 4.98E-04 3.66E-06 1.27E-04
12 D8S0809i 8 121379855 121380093 AAGTTATTTATACCAAGTGATGGTG TCCTAGGATCCTAAGATATAAATCTG 0.0455 3.89E-06 1.32E-04
13 D5S1310i 5 2137543 2137692 AGCCTTCACTCGTGTTCTTAC AAATAGGAGGACAGAGTAGCAGAG 4.72E-04 8.25E-06 2.41E-04
14 D7S1017i 7 135196215 135196636 ACTGTTCTCATGGTAGTGAATAAG CTCTTCCTCGTTTGTAGACAC 0.0039 8.78E-06 2.52E-04
15 D9S0704i 9 82887428 82887533 TGCCATGACTGTCTTTCC TGGAACAAATGATATCAAGAGATAG 0.006 3.02E-05 6.22E-04
16 D7S0072i 7 147781781 147782230 TTCATGAATCCTCAACTATTAAAG GCTTACTACCTGGTTAATGAAATA 0.0081 2.11E-04 0.0030
17 D20S0325i 20 47715303 47715449 GTTATGATCATGTCACTGCAC CCTTAGGACTTGATGTTTCTTC 0.0069 2.39E-04 0.0034
18 D10S0385i 10 7092531 7092986 GGATAACTCCAAGATTTCTGAC GATTAACATGTAAATAGGCAGACT 0.0143 2.90E-04 0.0038
19 D8S0335i 8 116305649 116306128 TTAATATTGATAACATCTTGCGA CCTTATGACAAATCTTTTCTGAG 0.0266 4.40E-04 0.0053
20 D3S0046i 3 6944093 6944453 ATGGCCATGTTATGATGTTAAT TGACAGAGCTAGACTCTTGTCAG 0.0247 4.98E-04 0.0054
21 D14S0356i 14 75942526 75942991 TACTCAAATGTCACATTGGTTA CAGACTAATCAATAACAGAGGACT 8.30E-04 5.00E-04 0.0054
22 D15S966 15 96766304 96766555 TGCTGCTCACGAACTTTT CCTCTTGGGAACTGTGTAGTATT 0.0142 4.87E-04 0.0054
23 D9S0416i 9 7107471 7107725 AATATTACCTTATTGTTGAGTAAATGC CCAACAATATAATTTAGGAAGAGC 0.0187 0.0014 0.0127
24 D13S0138i 13 100138248 100138637 AGACTCATCTCCTACCTTTCAC TAAGAATCCATATGTTGCTGAC 0.0017 0.0017 0.0147
25 D9S0242i 9 8735688 8736162 CGTTTGTAATTGAACGAATAAC CACCTTGTCACAATTACTCAAC 0.0087 0.0019 0.0160
26 HUMUT6930B 21 39672158 39672587 CGGAGGTTGCAGTGAGTTG GGGAAGGCTATGGAGGAGA 0.0007 0.0022 0.0174
27 D8S0912i 8 89632493 89632925 GGATGTCTTGTCTTACATTCTCTAG CAGGTGTCTACTAAACCATCTGAC 0.0231 0.0023 0.0178
28 D6S0444i 6 9065374 9065718 AATTAAGAGTGATCTGAGCAGAAG TCAAATTTGGTGACCTTAACAG 0.0016 0.0023 0.0182
29 D5S0803i 5 23507111 23507556 TGGTATTAATCTGTTAATGAGGAC GAATCAACCTAAGTGTACATCAAC 0.0357 0.0024 0.0186
30 D18S0429i 18 487260 487643 CGGATCACCATATAGTGAAAC GAATTAGAAAGTCACGTTGGTAC 0.0269 0.0026 0.0194
31 HUMUT544 11 123087682 123087978 ACTTCAGCCTCGGTGACAG TGTTCTGCCTCTGTTGTTAC 0.0453 0.0027 0.0202
32 D4S0317i 4 64967890 64968058 GATACAATTGGTACTGCAAAATAC TCCTAAGTTCCTAAAGAATCACTC 0.0000 0.0030 0.0215
33 D8S0674i 8 60955922 60956375 TTTCTAATCCATCTGTCAATAAAG AGTCACTATGCATAGACCACAC 0.0004 0.0031 0.0220
34 D7S2422 7 51105545 51105739 GCTCCACATTCCTTGGGTA AAGTGAGGGCCTTTCAAAC 0.0131 0.0037 0.0249
35 D10S0463i 10 73857334 73857571 AGAGTAAATCCTCTCCTCATACAAG TTGCACAGTTCAGAAGCC 0.0046 0.0045 0.0288
36 D8S0225i 8 30387109 30387478 CAGTTGGAATAAATCAGTGAAC CTGGCTAACATGGTGAAAC 0.0077 0.0070 0.0370
37 D10S0809i 10 48104477 48104600 GCTAGTGTTGGGAGTCAGC AGGTGAGCCAGTTTCCAG 0.0123 0.0068 0.0370
38 D20S0115i 20 36321601 36321804 ATACTGGCACAAACGCATC TTAGACTCAGCTATGGAAAGTCAG 0.0013 0.0068 0.0370
39 D12S0456i 12 64866094 64866556 ATTTACCTATGTAACAAACTGCAC CACAGACTTAATGGATAAGCAG 0.0042 0.0075 0.0383
40 D4S0132i 4 30434753 30434922 CCAGAAGATAGAAGGAGAATCAC TCTTGATGGTTGGCTGTC 0.0300 0.0085 0.0401
41 D7S0338i 7 83663532 83663831 CTTAACAATACTGGCTGATCAATAG CATTGTCACTACAGCTTTCATTAC 0.0013 0.0088 0.0413
42 D12S0341i 12 33909083 33909516 TCAAACCTTCATCTTTGTACTTAG AACTGGCTTCTATCTCACCTAT 0.0223 0.0089 0.0416
43 D1S0288i 1 33214510 33214921 ATACTGTACTTCATGCCATAAGAC GAGAAATACGGCTGGTGTA 0.0000 0.0092 0.0425
44 D1S1215i 1 241929347 241929516 CTGCAGTCACAACTGGTTAAG TTGATAACAGCATACTTCAACATAG 0.0027 0.0097 0.0430
45 D12S1657 12 96183565 96183714 TCCTAAAGATGGTGTGCAT AAGTTCCAATGTTAGTGAACC 0.0431 0.0100 0.0435
46 D16S0497i 16 59449366 59449516 GTAAATCCAATATCTTGCCTACAG TTCAGGTTCTCCATGTCAAC 0.0361 0.0104 0.0446
47 D10S0107i 10 119415495 119415711 ACAGGCAATCTGATAGTTTAAGAG AATTGACTCAAGGTTCTGCAG 0.0254 0.0112 0.0469
* hg18: human genome assembly version 18
Abbreviation: Chr = Chromosome,
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associated gene SEMA3A
The D7S0338i marker is 1500 bp upstream of the tran-
scription start site of the SEMA3A gene (table 3). The link-
age disequilibrium block around this marker did not
extend to neighbouring genes (see additional file 2). To
assess possible functional impacts of the SEMA3A gene on
cellular radiosensitivity (see additional file 3), a model sys-
tem using in vitro irradiation of cultured fibroblasts derived
from human skin was employed. Specific SEMA3A siRNA
treatment of these cells reduced expression of the
SEMA3A gene in normal human skin fibroblasts (see addi-
tional file 4). When these cells were irradiated with X-rays
(200 keV), the colony survival assay of the irradiated cells
showed enhancement of cellular radiation resistance in the
SEMA3A siRNA-treated cells (see figure 2).
Discussion
A human genome-wide microsatellite association study
was performed in cancer patients who showed
radiation-induced adverse reactions. After correction for
multiple comparisons, this study identified 47 autosomal
markers with a FDR < 0.05. One of these markers is
within the proximal promoter region of the SEMA3A
gene on chromosome 7. Knockdown of SEMA3A
expression in a normal human skin fibroblast culture
caused a significant change in the radiosensitivity of
these cells.
The SEMA3A gene has not been previously described
as having a role in radiosensitivity. SEMA3A encodes a
secreted protein (semaphorin-3A), which is involved in
a wide range of functional processes including regula-
tion of axon guidance, cell survival, motility, immune
responses and angiogenesis [28-49] (see additional file
3). This diversity of these roles provides many possible
mechanisms for its involvement in radiosensitivity.
Semaphorin-3A is also a competitor of the angiogenic
growth factor coded for by the VEGF gene, as both bind
to the same transmembrane receptor [29,31,46]. As
VEGF expression is directly correlated with
Table 3 Reproducibility of markers located within 15 kb distance to the nearest transcription start sit
Chr Marker Repeat Unit Nearest gene Distance to TS 2
nd screen FDR P values
1
st screen 2
nd screen Overall
1 D1S0288i GAA IBRDC3 12196 bp 0.043 0.019 0.041 0.001
(IBR domain
containing 3)
5 D5S0365i TG C5orf13 6571 bp 9.28E-07 0.031 0.639 0.054
(Protein p311)
7 D7S0338i GA SEMA3A 1453 bp 0.041 0.012 2.70E-04 1.24E-05
(Semaphorin-3A)
12 D12S0456i TG IRAK3 2796 bp 0.038 0.018 0.194 0.008
(Interleukin-1 receptor-
associated kinase 3)
Abbreviation: Chr = chromosome, TS = transcription start site, FDR = false discovery rate
Table 4 Allelic association analysis for the D7S0338i marker using Fisher’s exact test
1
st screen 2
nd screen Overall results
Allele (bp) LGG n(%) HGG n(%) P value LGG n(%) HGG n(%) P value LGG n(%) HGG n(%) P value
278 0 (0.0) 1 (0.6) 1.000 1 (0.6) 1 (0.6) 1.000 1 (0.3) 2 (0.6) 1.000
282 0 (0.0) 0 (0.0) 1.000 1 (0.6) 1 (0.6) 1.000 1 (0.3) 1 (0.3) 1.000
284 1 (0.6) 0 (0.0) 0.494 0 (0.0) 0 (0.0) 1.000 1 (0.3) 0 (0.0) 0.496
288 1 (0.6) 1 (0.6) 1.000 0 (0.0) 1 (0.6) 1.000 1 (0.3) 2 (0.6) 1.000
290 0 (0.0) 1 (0.6) 1.000 0 (0.0) 0 (0.0) 1.000 0 (0.0) 1 (0.3) 1.000
292 88 (50.0) 68 (37.8) 0.025 79 (44.4) 58 (32.2) 0.022 167 (47.2) 126 (35.0) 0.001
294 37 (21.0) 39 (21.7) 0.898 45 (25.3) 37 (20.6) 0.315 82 (23.2) 76 (21.1) 0.529
296 44 (25.0) 68 (37.8) 0.012 47 (26.4) 81 (45.0) 2.70E-04 91 (25.7) 149 (41.4) 1.24E-05
298 4 (2.3) 1 (0.6) 0.211 4 (2.2) 1 (0.6) 0.214 8 (2.3) 2 (0.6) 0.062
300 0 (0.0) 1 (0.6) 1.000 0 (0.0) 0 (0.0) 1.000 0 (0.0) 1 (0.3) 1.000
302 1 (0.6) 0 (0.0) 0.494 1 (0.6) 0 (0.0) 0.497 2 (0.6) 0 (0.0) 0.245
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Page 7 of 11radiosensitivity [50], its competitor, semaphorin-3A, may
also be associated with radiosensitivity.
The potential role of the D7S0338i marker in radio-
sensitivity is interesting. The microsatellite is located
1500 bp upstream from the transcription start site of
SEMA3A, and is a GA dinucleotide repeat (see addi-
tional file 5). Two other polymorphic repetitive
sequences also occur between the D7S0338i marker and
the SEMA3A transcription start site (additional file 6).
These three repetitive sequences are in a low nucleo-
some occupancy region (data not shown). Since nucleo-
somes play a major role in generating the higher order
structure of chromatin that regulates gene expression
[51], these sequences may affect the activity of the
SEMA3A promoter. A study into the activity of the
SEMA3A promoter may provide information on the
functional impacts of the D7S0338i marker polymorph-
ism, especially mechanisms underlying the phenotypes
associated with various alleles (table 5).
A major limitation of association studies on rare pheno-
types such as the severe (equal to or greater than grade 3),
acute, adverse reactions induced by radiotherapy, is the
ability to enroll sufficient numbers of patients to provide
adequate statistical power [7,52]. The reproducibility of
any association identified must also be replicated [53],
further increasing the required patient number. Hence in
this study, cancer patients were selected with differing
severe, acute, adverse reaction endpoints and various can-
cer types. Identical numbers of control patients were
selected who did not develop severe, adverse reactions on
any endpoint. The clinical characteristics and therapeutic
protocols used in the control and subject patients were
also similar (table 1). While this suggests inherent or
genetic differences between patients are the cause of the
variations in severity in patient reactions, the involvement
of SEMA3A requires further validation using large num-
bers of patients with a unique cancer type.
A possible implication for this study’sf i n d i n gt h a t
semaphorin-3A may be involved in radiosensitivity, is
the identification of a potential new agent for the treat-
ment of radiotherapy-induced damage. SM-216289
(xanthofulvin) was originally isolated from the fermenta-
tion broth of a fungal strain, Penicillium sp. SPF-3059,
and is a natural inhibitor of Semaphorin-3A [54]. SM-
216289 abolished the growth cone collapse of dorsal
root ganglion neurons that was induced by Semaphorin-
3A in vitro and in vivo, possibly through direct interfer-
ence of the receptor-ligand association [54]. Local
administration of SM-216289 in the adult rat model of
spinal cord injury, substantially enhanced functional
recovery of injured axons, with decreases in apoptotic
cell number and marked enhancement of angiogenesis
[55]. Therefore, locally administered SM-216289 may
aid functional recovery in radiotherapy-induced injury.
Increasingly, phenotypic differences have been shown
to be caused by diverse genetic variations. While SNP
and repetitive DNA polymorphisms have been shown to
be disease-associated, other disease-associated changes
include copy number variation [56] and transgenerational
epigenetic modification of the genome [57]. Thus, diag-
nostic testing should be considered to identify highly
Table 5 Genotype association analysis of D7S0338i
marker
Number Genotype LGG HGG P
value
Odds
ratio
95% CI
n (%) n (%)
1* 292/292 36
(20.3)
20
(11.1)
0.017 0.490 0.271-
0.885
2* 292/294 41
(23.2)
29
(16.1)
0.093 0.637 0.375-
1.081
3* 294/294 11 (6.2) 9 (5.0) 0.788 0.794 0.321-
1.966
4* 292/296 48
(27.1)
54
(30.0)
0.547 1.152 0.727-
1.824
5* 294/296 17 (9.6) 28
(15.6)
0.090 1.734 0.912-
3.295
6* 296/296 12 (6.8) 31
(17.2)
0.002 2.861 1.417-
5.774
7 Others 12 (6.8) 9 (5.0) 0.624 0.724 0.297-
1.763
*Cochran-Armitage trend test: P = 7.228 × 10
-4
Figure 2 In vitro radiosensitivity assay on human skin
fibroblast cells treated with SEMA3A gene-directed siRNA. The
relative clonogenic survival rate of cells at the indicated X-ray dose
(Gy) is plotted. Open box: mock control. Closed triangle: SEMA3A
siRNA1. Closed circle: SEMA3A siRNA2. The linear-quadratic model
[27] of cell survival as a function of irradiated dose was fitted to the
data. The asterisk indicates significant difference between the siRNA
transfected cells and the control cells (P value < 0.05).
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Page 8 of 11radiosensitive cancer patients through the detection of
genetic variants in individual patients. The rapidly devel-
oping next-generation genome sequencing technology
[58] may be the most suitable one for this purpose.
Conclusions
A total of 47 putative markers for individual radiosensi-
tivity were identified using a genome-wide screen based
on microsatellite markers. One of these markers is in
the proximal promoter region of SEMA3A, with knock-
down of this gene using siRNA supporting its potential
role in radiosensitivity.
Additional material
Additional file 1: Allele frequencies for the D7S0338i marker. (A)
First screening samples. (B) Second screening samples. (C) Overall results.
The number of patients with the indicated allele size is plotted.
Reproducible allele frequency differences were observed between the
groups. White bar: LGG. Black bar: HGG. Significant differences (P < 0.05
by Fisher’s exact test based on 2 × 2 contingency tables) are indicated
by the vertical lines.
Additional file 2: Linkage disequilibrium map around the D7S0338i
marker. Diagram showing the region of linkage disequilibrium (D’)
surrounding the SEMA3A gene and neighbouring genes. An increase in
the degree of linkage disequilibrium between the SEMA3A gene and its
neighbours is represented by an increase in the intensity of red color.
Thus, the D7S0338i marker is in the linkage disequilibrium block that
spans the transcriptional regulatory region of the SEMA3A gene. The D’
data was calculated from JPT and CHB HapMap data. Positions are NCBI
build 36 coordinates. Gene region and direction of transcription are
indicated by an arrow.
Additional file 3: References on semaphorin-3A functions
Additional file 4: Reduction in the amount of semaphorin-3A
protein following siRNA treatment. The amount of semaphorin-3A in
the culture medium of cells treated by the siRNA was quantified by
Western blotting. The protein amounts relative to that of mock control
cells are plotted.
Additional file 5: Sequence of the D7S0338i marker. This marker is
the GA dinucleotide repeat sequence indicated by the red color. The
primer sequences for PCR amplification are indicated by the arrows.
Additional file 6: Location of the D7S0338i marker in the promoter
region of the SEMA3A gene. The GA dinucleotide repeat sequence is
indicated by an open box. Two other polymorphic repetitive sequences
(closed box) exist in the region between the D7S0338i marker and the
transcription start site (+1).
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